Memory enhancement by Tamoxifen on amyloidosis mouse model

Area of Science:

• Neuroscience
• Pharmacology
• Alzheimer's Disease Research

Background:

• Tamoxifen (TMX), a selective estrogen receptor modulator (SERM), is used for breast cancer treatment.
• Previous studies indicate TMX possesses neuroprotective properties, affecting apoptosis, microglial function, and synaptic plasticity.
• TMX has demonstrated memory enhancement and protection against amyloid-induced damage in preclinical models.

Purpose of the Study:

• To investigate the therapeutic potential of TMX in Alzheimer's disease (AD).
• To evaluate the effects of TMX on memory function in a mouse model of Aβ1-42-induced neurotoxicity.
• To analyze the impact of TMX on key neurotransmitter levels (acetylcholine and dopamine) in the brain.

Main Methods:

• Breeding-retired female mice were injected with beta-amyloid1-42 (Aβ1-42) to induce AD-like pathology.
• Mice received TMX treatment (10mg/kg, i.p.) for 15 days.
• Cognitive function was assessed using the Morris water maze and passive avoidance tests.
• Neurotransmitter levels (acetylcholine and dopamine) and their metabolites were measured in brain regions.

Main Results:

• TMX treatment significantly improved spatial and contextual memory in Aβ1-42 injected mice, evidenced by reduced escape latency and increased time in the platform quadrant.
• TMX-treated mice showed enhanced avoidance of aversive stimuli in the passive avoidance test.
• Acetylcholine (ACh) levels were moderately increased in the frontal cortex.
• Dopamine (DA) levels were significantly increased in the striatum, with a decreased DOPAC/DA ratio, indicating reduced dopamine metabolism.

Conclusions:

• TMX demonstrates significant neuroprotective effects against Aβ1-42-induced cognitive deficits.
• TMX enhances memory performance by modulating neurotransmitter systems, specifically increasing ACh and reducing dopamine metabolism.
• These findings suggest TMX as a potential therapeutic agent for Alzheimer's disease.